Alexandre Tremblay

Alexandre Tremblay

Auto-generated profile, based on publicly available information

Alexandre Tremblay

Institut de Pharmacologie de Sherbrooke, Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001, 12e avenue Nord, Sherbrooke, QC J1H 5N4, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ALAnnik Lanoie
Annik Lanoie
SFSára Ferková
Sára Ferková
ÉCÉdouard Caron-Duval
Édouard Caron-Duval
JDJuliana C.C. Dallagnol
Juliana C.C. Dallagnol
SDSitan Diarra
Sitan Diarra
PSPhilippe Sarret
Philippe Sarret
Contulakins are a subclass of conopeptides derived from cone snail venom, known for their analgesic properties mediated through activation of neurotensin receptors NTS1 and NTS2. Among them, contulakin-G, isolated from Conus geographus, exhibits a favorable pharmacokinetic profile, including a 24-hour plasma half-life, and produces potent opioid-independent antinociceptive effects. To facilitate synthesis while preserving analgesic efficacy, we investigated the structure-activity relationships of contulakin-G, focusing on modifications to the glycosylated Thr10 residue. In the first series, Thr10 was substituted by natural and non-natural amino acids encompassing diverse physiochemical and steric properties. Most substitutions had minimal impact on receptor affinity, though some increased the NTS2/NTS1 selectivity ratio. Of these, only the Tyr10 analog retained antinociceptive efficacy comparable to native contulakin-G. Building on tyrosine's hydrophobicity, a second series introduced non-natural hydrophobic residues at position 10, including Gln-cycloheptyl, Gln-biphenylmethyl, and Gln-dimethyladamantyl, along with a non-glycosylated form. In both tonic and postoperative pain models, the non-glycosylated and Gln-cycloheptyl analogs demonstrated potent analgesic activity, comparable to contulakin-G and reversed mechanical allodynia in a neuropathic pain model. In contrast, a third series involving N-terminal truncations led to reduced plasma half-life and loss of antinociceptive efficacy, underscoring the importance of the N-terminal region. Molecular modeling further revealed that full-length analogs engage a broader NTS2 binding interface than truncated derivatives. These findings support the development of synthetically accessible contulakin-G analogs as promising non-opioid analgesics.

11 May 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ÉBÉmile Breault
Émile Breault
JNJolien De Neve
Jolien De Neve
ARAmirmohammad Ranjbaran
Amirmohammad Ranjbaran
ATAlexandre Tremblay
Alexandre Tremblay
IRInes Robberechts
Ines Robberechts
PSPhilippe Sarret
Philippe Sarret
The ongoing opioid crisis underscores the urgent need for safer and more effective analgesics. One promising strategy involves designing bifunctional compounds that engage complementary antinociceptive systems to enhance efficacy while minimizing adverse effects. In this context, the neurotensin (NT) system is particularly attractive, as it produces long-lasting, opioid-independent analgesia and acts synergistically with opioid signaling. Here, we report the in vivo characterization of bifunctional opioid-neurotensin (OPNT) hybrid peptides, in which a dual MOP/DOP agonist is fused to a selective NTS2 agonist. These hybrids retained high affinity for MOP and DOP receptors, selective binding to NTS2 receptors, and partial agonist activity at MOP, a profile associated with reduced opioid-related liabilities. Among the series, SBL-OPNT-13 emerged as the lead compound, producing robust and sustained antinociceptive effects across multiple pain models, including acute thermal nociception, formalin-induced pain, postoperative hypersensitivity, and chronic inflammatory pain. Following intraperitoneal administration, SBL-OPNT-13 outperformed morphine, displaying greater potency and a prolonged duration of action lasting up to 24 h. Importantly, SBL-OPNT-13 was shown to cross the blood-brain barrier, supporting the role of the opioid pharmacophore as a shuttle for brain delivery of the NT moiety. From a safety perspective, SBL-OPNT-13 displayed reduced NTS1-mediated effects, such as hypotension and hypothermia, compared with earlier OPNT hybrids. Although opioid constipation was observed, repeated intrathecal administration resulted in partial tolerance, with a substantial residual antinociceptive effect, potentially reflecting the contribution of the NT pharmacophore. Together, these findings validate the dual-target strategy and identify SBL-OPNT-13 as a promising next-generation analgesic.